Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Sapna Patel, MD, an associate professor, uveal melanoma program director, fellowship program director, and director of online media in the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center, to discuss a new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.

On April 8, 2021, The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences announced a strategic research collaboration to evaluate SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibitors for the treatment of patients with pancreatic cancer and hepatocellular carcinoma (HCC).

The initial study of the collaboration will enroll patients with uveal melanoma–related liver metastases, with other studies planned in metastatic pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer. Additional trials in HCC and locally advanced PDAC are being developed.

In our exclusive interview, Patel discussed the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences and the resulting research evaluating the administration of the investigational TLR9 agonist in combination with immunotherapy across a range of liver and pancreatic solid tumors.